BOOK
Reproductive Health, An Issue of Rheumatic Disease Clinics of North America, E-Book
Eliza F. Chakravarty | Lisa R. Sammaritano
(2017)
Additional Information
Book Details
Abstract
Thi sissue of Rheumatic Disease Clinics will focus on reproductive health and will include articles on the following: Contraception; infertility - prevention and management; reproductive health screening; biomarkers; use of corticosteroids; and many more exciting articles!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Reproductive Health\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Foreword: Reproductive Health\r | v | ||
| Preface: Reproductive Rheumatology: Meeting Today’s Challenges\r | v | ||
| Reproductive Health Screening in Women with Autoimmune Diseases | v | ||
| Contraception in Patients with Rheumatic Disease | v | ||
| Preconception Counseling | v | ||
| Biomarkers for Adverse Pregnancy Outcomes in Rheumatic Diseases | vi | ||
| Systemic Lupus Erythematosus and Pregnancy | vi | ||
| Fertility, Pregnancy, and Lactation in Rheumatoid Arthritis | vi | ||
| Vasculitis and Pregnancy | vi | ||
| Lactation and Management of Postpartum Disease | vii | ||
| Outcomes in Children Born to Women with Rheumatic Diseases | vii | ||
| Infertility – Prevention and Management | vii | ||
| Menopause and Rheumatic Disease | viii | ||
| RHEUMATIC DISEASE CLINICS\rOF NORTH AMERICA\r | ix | ||
| FORTHCOMING ISSUES | ix | ||
| August 2017 | ix | ||
| November 2017 | ix | ||
| February 2018 | ix | ||
| RECENT ISSUES | ix | ||
| February 2017 | ix | ||
| November 2016 | ix | ||
| August 2016 | ix | ||
| Foreword:\rReproductive Health | xi | ||
| Preface:\rReproductive Rheumatology: Meeting Today’s Challenges | xiii | ||
| Reproductive Health Screening in Women with Autoimmune Diseases | 161 | ||
| Key points | 161 | ||
| INTRODUCTION | 161 | ||
| BREAST CANCER | 162 | ||
| Breast Cancer and Systemic Lupus Erythematosus | 162 | ||
| Rheumatoid Arthritis and Breast Cancer | 163 | ||
| Recommendations for Screening for Breast Cancer | 164 | ||
| CERVICAL CANCER | 165 | ||
| Cervical Cancer and Immunosuppressive Agents | 165 | ||
| Systemic Lupus Erythematosus and Human Papilloma Virus Infection | 166 | ||
| Vaccination Against Human Papilloma Virus | 166 | ||
| Screening Recommendations for Autoimmune Patients | 167 | ||
| ADHERENCE AND BARRIERS TO REPRODUCTIVE HEALTH SCREENING | 167 | ||
| SUMMARY | 168 | ||
| REFERENCES | 169 | ||
| Contraception in Patients with Rheumatic Disease | 173 | ||
| Key points | 173 | ||
| INTRODUCTION | 173 | ||
| Effective Contraception | 173 | ||
| UNDERUSE OF EFFECTIVE CONTRACEPTION | 174 | ||
| TYPES OF CONTRACEPTIVES | 175 | ||
| Barrier Contraception | 175 | ||
| Intrauterine Devices | 176 | ||
| Hormonal Contraception | 176 | ||
| Combined hormonal contraceptives | 176 | ||
| Progestin-only contraceptives | 177 | ||
| Emergency Contraception | 178 | ||
| SPECIFIC ISSUES FOR RHEUMATIC DISEASES | 178 | ||
| Risk of Disease Exacerbation | 178 | ||
| Risk of Thromboembolism | 179 | ||
| Medication Interactions | 181 | ||
| SUMMARY | 182 | ||
| REFERENCES | 185 | ||
| Preconception Counseling | 189 | ||
| Key points | 189 | ||
| INTRODUCTION | 189 | ||
| FERTILITY | 190 | ||
| CONTRACEPTION | 190 | ||
| THE COURSE OF RHEUMATIC DISEASE IN PREGNANCY | 190 | ||
| RISK ASSESSMENT | 190 | ||
| Patients Who Should Postpone Pregnancy | 192 | ||
| Maternal Risks in Pregnancy | 192 | ||
| Fetal Risks in Pregnancy | 193 | ||
| Autoantibodies as Risk Factors | 194 | ||
| ADJUSTMENT OF DRUG THERAPY | 194 | ||
| DECISION SHARING BETWEEN THE PATIENT AND SPECIALISTS | 195 | ||
| MONITORING DURING PREGNANCY | 195 | ||
| GENERAL RECOMMENDATIONS | 196 | ||
| SUMMARY | 196 | ||
| REFERENCES | 196 | ||
| Biomarkers for Adverse Pregnancy Outcomes in Rheumatic Diseases | 201 | ||
| Key points | 201 | ||
| DEFINITIONS OF ADVERSE OUTCOMES IN PREGNANCY | 202 | ||
| PATHOPHYSIOLOGY OF PREECLAMPSIA | 203 | ||
| BIOMARKERS FOR THE PREDICTION OF PREECLAMPSIA | 205 | ||
| PLACENTAL GROWTH FACTOR | 206 | ||
| SOLUBLE FMS-LIKE TYROSINE KINASE-1 | 206 | ||
| SOLUBLE ENDOGLIN | 207 | ||
| THE USE OF COMBINATION BIOMARKERS TO PREDICT ADVERSE OUTCOMES | 208 | ||
| UTILITY OF BIOMARKERS IN PREEXISTING HYPERTENSION AND CHRONIC KIDNEY DISEASE | 209 | ||
| UTILITY OF BIOMARKERS IN RHEUMATIC DISEASES, PARTICULARLY SYSTEMIC LUPUS ERYTHEMATOSUS | 209 | ||
| CLINICAL UTILITY IN RISK PREDICTION OF PREECLAMPSIA OR ADVERSE PREGNANCY OUTCOMES | 209 | ||
| ARE ANGIOGENIC BIOMARKERS THE ANSWER FOR PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH RHEUMATIC DISEASES? | 210 | ||
| ADVERSE PREGNANCY OUTCOMES AND FUTURE VASCULAR DISEASE | 210 | ||
| ACKNOWLEDGMENTS | 211 | ||
| REFERENCES | 212 | ||
| Systemic Lupus Erythematosus and Pregnancy | 215 | ||
| Key points | 215 | ||
| INTRODUCTION | 215 | ||
| EFFECTS OF PREGNANCY ON SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY | 216 | ||
| Recognition of Disease Activity During Pregnancy | 216 | ||
| Management of Disease Activity Pregnancy | 216 | ||
| EFFECT OF SYSTEMIC LUPUS ERYTHEMATOSUS ON PREGNANCY OUTCOMES | 218 | ||
| Preeclampsia in Systemic Lupus Erythematosus Pregnancy | 218 | ||
| MANAGEMENT GUIDELINES FOR PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS | 218 | ||
| Antiphospholipid Antibodies in Systemic Lupus Erythematosus Pregnancy | 219 | ||
| Anti-Ro/La Antibodies and Neonatal Lupus Syndromes | 220 | ||
| Medication Use During Pregnancy | 221 | ||
| SUMMARY | 222 | ||
| REFERENCES | 222 | ||
| Fertility, Pregnancy, and Lactation in Rheumatoid Arthritis | 227 | ||
| Key points | 227 | ||
| INTRODUCTION | 227 | ||
| FERTILITY | 228 | ||
| Female Perspective | 228 | ||
| Male Perspective | 228 | ||
| PREGNANCY | 229 | ||
| Disease Activity | 229 | ||
| Pregnancy Outcome | 230 | ||
| Impact for the Child | 230 | ||
| ANTIRHEUMATIC DRUGS DURING PREGNANCY AND LACTATION | 231 | ||
| Nonsteroidal Anti-inflammatory Drugs | 232 | ||
| Glucocorticoids | 232 | ||
| Disease-Modifying Antirheumatic Drugs | 232 | ||
| Tumor Necrosis Factor Blockers | 233 | ||
| Other Biologicals | 233 | ||
| SUMMARY | 233 | ||
| REFERENCES | 234 | ||
| Vasculitis and Pregnancy | 239 | ||
| Key points | 239 | ||
| INTRODUCTION | 239 | ||
| ANTINEUTROPHIL CYTOPLASMIC ANTIBODY–ASSOCIATED VASCULITIS, INCLUDING GRANULOMATOSIS WITH POLYANGIITIS, MICROSCOPIC POLYANGI ... | 240 | ||
| Effect of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis on Pregnancy | 240 | ||
| Effect of Pregnancy on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis | 240 | ||
| POLYARTERITIS NODOSA | 241 | ||
| TAKAYASU ARTERITIS | 241 | ||
| Effect of Takayasu Arteritis on Pregnancy | 241 | ||
| Effect of Pregnancy on Takayasu Arteritis | 242 | ||
| BEHÇET DISEASE | 242 | ||
| Effect of Behçet Disease on Pregnancy | 243 | ||
| Effects of Pregnancy on Behçet Disease | 243 | ||
| VASCULITIS TREATMENT IN PREGNANCY | 243 | ||
| SUMMARY | 245 | ||
| REFERENCES | 245 | ||
| Lactation and Management of Postpartum Disease | 249 | ||
| Key points | 249 | ||
| IMMUNE SYSTEM DURING PREGNANCY AND THE POSTPARTUM PERIOD | 249 | ||
| DISEASE ACTIVITY DURING PREGNANCY AND THE POSTPARTUM PERIOD | 250 | ||
| LACTATION | 250 | ||
| BREASTFEEDING | 250 | ||
| BREAST MILK | 251 | ||
| MEDICATIONS DURING LACTATION | 251 | ||
| NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND ASPIRIN | 251 | ||
| GLUCOCORTICOIDS | 254 | ||
| ANTIMALARIALS | 254 | ||
| SULFASALAZINE | 254 | ||
| IMMUNOSUPPRESSIVE DRUGS | 254 | ||
| METHOTREXATE | 255 | ||
| CYCLOPHOSPHAMIDE | 255 | ||
| BIOLOGICS | 255 | ||
| TUMOR NECROSIS FACTOR-α INHIBITORS | 255 | ||
| TOCILIZUMAB | 256 | ||
| ANAKINRA | 256 | ||
| INTRAVENOUS IMMUNOGLOBULIN | 256 | ||
| MEDICATIONS WITH UNKNOWN RISK | 256 | ||
| OTHER MEDICATIONS | 256 | ||
| Antihypertensives | 256 | ||
| Anticoagulants | 257 | ||
| Colchicine | 257 | ||
| SUMMARY | 257 | ||
| REFERENCES | 257 | ||
| Outcomes in Children Born to Women with Rheumatic Diseases | 263 | ||
| Key points | 263 | ||
| INTRODUCTION | 263 | ||
| Neurodevelopmental Disorders | 264 | ||
| Congenital Heart Defects | 267 | ||
| Hematological Malignancies | 268 | ||
| Rheumatic and Nonrheumatic Autoimmune Diseases | 269 | ||
| SUMMARY | 269 | ||
| REFERENCES | 270 | ||
| Infertility – Prevention and Management | 275 | ||
| Key points | 275 | ||
| INTRODUCTION | 275 | ||
| PRIMARY OVARIAN INSUFFICIENCY | 276 | ||
| ALTERATIONS IN THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS | 277 | ||
| PARITY IN WOMEN WITH AUTOIMMUNE DISEASES | 278 | ||
| EFFECTS OF MEDICATIONS ON OVARIAN FUNCTION | 279 | ||
| Alkylating Agents | 279 | ||
| PRESERVATION OF FERTILITY IN WOMEN RECEIVING GONADOTOXIC THERAPIES | 279 | ||
| Assisted Reproductive Technologies | 279 | ||
| Gonadotropin-releasing Hormone Analog Therapy | 280 | ||
| SUMMARY | 281 | ||
| REFERENCES | 281 | ||
| Menopause and Rheumatic Disease | 287 | ||
| Key points | 287 | ||
| INTRODUCTION | 287 | ||
| SYSTEMIC LUPUS ERYTHEMATOSUS | 288 | ||
| RHEUMATOID ARTHRITIS | 290 | ||
| OSTEOARTHRITIS | 291 | ||
| Sjögren Syndrome | 294 | ||
| Scleroderma | 294 | ||
| SUMMARY | 295 | ||
| REFERENCES | 295 | ||
| Index | 303 |